These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37545011)

  • 21. Can ketamine be a safe option for treatment-resistant bipolar depression?
    Singh B; Vande Voort JL; Frye MA; Kung S
    Expert Opin Drug Saf; 2022 Jun; 21(6):717-720. PubMed ID: 35188015
    [No Abstract]   [Full Text] [Related]  

  • 22. The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality.
    Zhou Y; Wang C; Lan X; Zheng W; Li H; Chao Z; Wu K; McIntyre RS; Ning Y
    J Psychiatr Res; 2021 Dec; 144():312-319. PubMed ID: 34715598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical predictors of ketamine response in treatment-resistant major depression.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
    J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
    McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
    Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
    Włodarczyk A; Cubała WJ
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
    Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
    Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ketamine for the treatment of depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketamine's effectiveness in unipolar versus bipolar depression.
    Fond G; Boyer L
    Psychopharmacology (Berl); 2014 Nov; 231(22):4417-8. PubMed ID: 25315362
    [No Abstract]   [Full Text] [Related]  

  • 30. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Gill H; Nasri F; Ling R; Teopiz KM; Ho RC; Subramaniapillai M; Kratiuk K; Mansur RB; Jones BDM; Lee Y; Rosenblat JD
    J Affect Disord; 2021 Nov; 294():592-596. PubMed ID: 34332360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Cha DS; Nasri F; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    Expert Opin Drug Saf; 2020 Aug; 19(8):1031-1040. PubMed ID: 32539491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
    Feifel D; Malcolm B; Boggie D; Lee K
    J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
    Szymkowicz SM; Finnegan N; Dale RM
    J Affect Disord; 2013 May; 147(1-3):416-20. PubMed ID: 23182590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression.
    Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Lan XF; Zhang B; Ning YP
    J Affect Disord; 2020 Oct; 275():38-43. PubMed ID: 32658821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment.
    McIntyre RS; Rodrigues NB; Lipsitz O; Lee Y; Cha DS; Gill H; Lui LMW; Subramaniapillai M; Kratiuk K; Ho R; Mansur RB; Rosenblat JD
    J Affect Disord; 2021 Jun; 288():210-216. PubMed ID: 33965843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
    Andrade C
    Bipolar Disord; 2022 Mar; 24(2):113-114. PubMed ID: 34816542
    [No Abstract]   [Full Text] [Related]  

  • 40. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.